NCT07594093PHASE1RecruitingAccepts Healthy Volunteers
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
Regeneron Pharmaceuticals
Start Date
6/29/2026
Completion Date
2/22/2027
Summary
This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity. The study is looking at: * What side effects REGN20934 might cause * How much REGN20934 is in the blood at different times * If the body makes antibodies to REGN20934
Eligibility Criteria
Age Range: 18 years to 65 years
Key Inclusion Criteria:
1. Has a Body Mass Index (BMI) 25 to 35 kg/m\^2
2. Females must be of non-childbearing potential
Key Exclusion Criteria:
1. A self-reported change of body weight \>5 kg within approximately 90 days of visit 2
2. History of type 1 or type 2 diabetes
3. History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease, as defined in the protocol
Note: Other protocol defined inclusion/exclusion criteria apply
Interventions
DRUG
REGN20934
DRUG
Placebo
Conditions
Overweight or Obesity
Locations
California Clinical Trials Medical Group
Glendale, California 91206
United States